Silencing Core Spliceosome Sm Gene Expression Induces a Cytotoxic Splicing Switch in the Proteasome Subunit Beta 3 mRNA in Non-Small Cell Lung Cancer Cells
Open Access
- 11 June 2020
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (12), 4192
- https://doi.org/10.3390/ijms21124192
Abstract
The core spliceosomal Sm proteins were recently proposed as cancer-selective lethal targets in non-small cell lung cancer (NSCLC). In contrast, the loss of the commonly mutated cancer target SF3B1 appeared to be toxic to non-malignant cells as well. In the current study, the transcriptomes of A549 NSCLC cells, in which SF3B1 or SNRPD3 was silenced, were compared using RNA sequencing. The skipping of exon 4 of the proteasomal subunit beta type-3 (PSMB3) mRNA, resulting in a shorter PSMB3-S variant, occurred only after silencing SNRPD3. This observation was extended to the other six Sm genes. Remarkably, the alternative splicing of PSMB3 mRNA upon Sm gene silencing was not observed in non-malignant IMR-90 lung fibroblasts. Furthermore, PSMB3 was found to be overexpressed in NSCLC clinical samples and PSMB3 expression correlated with Sm gene expression. Moreover, a high PSMB3 expression corresponds to worse survival in patients with lung adenocarcinomas. Finally, silencing the canonical full-length PSMB3-L, but not the shorter PSMB3-S variant, was cytotoxic and was accompanied by a decrease in proteasomal activity. Together, silencing Sm genes, but not SF3B1, causes a cytotoxic alternative splicing switch in the PSMB3 mRNA in NSCLC cells only.This publication has 35 references indexed in Scilit:
- High-throughput RNAi screening reveals cancer-selective lethal targets in the RNA spliceosomeOncogene, 2019
- Diagnosis and classification of hematologic malignancies on the basis of geneticsBlood, 2017
- Alternative splicing as a regulator of development and tissue identityNature Reviews Molecular Cell Biology, 2017
- Therapeutic targeting of splicing in cancerNature Medicine, 2016
- Small Molecule Modulators of Pre-mRNA Splicing in Cancer TherapyTrends in Molecular Medicine, 2015
- Alternative splicing in cancer: implications for biology and therapyOncogene, 2014
- A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumorsInvestigational New Drugs, 2013
- Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid TumorsClinical Cancer Research, 2013
- Alternative isoform regulation in human tissue transcriptomesNature, 2008
- Understanding alternative splicing: towards a cellular codeNature Reviews Molecular Cell Biology, 2005